KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables - Net (2017 - 2025)

Historic Receivables - Net for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $2.0 billion.

  • Moderna's Receivables - Net fell 2591.51% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 2591.51%. This contributed to the annual value of $698.0 million for FY2024, which is 5593.43% down from last year.
  • As of Q3 2025, Moderna's Receivables - Net stood at $2.0 billion, which was down 2591.51% from $260.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Receivables - Net ranged from a high of $3.2 billion in Q1 2021 and a low of $232.0 million during Q2 2023
  • In the last 5 years, Moderna's Receivables - Net had a median value of $2.0 billion in 2021 and averaged $1.8 billion.
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 5704794.37% in 2021, then tumbled by 9137.87% in 2023.
  • Moderna's Receivables - Net (Quarter) stood at $3.2 billion in 2021, then plummeted by 56.38% to $1.4 billion in 2022, then increased by 14.37% to $1.6 billion in 2023, then crashed by 55.93% to $698.0 million in 2024, then surged by 189.97% to $2.0 billion in 2025.
  • Its Receivables - Net was $2.0 billion in Q3 2025, compared to $260.0 million in Q2 2025 and $249.0 million in Q1 2025.